Kane Biotech to Release First Quarter 2020 Financial Results on May 21 – Conference Call to Follow

WINNIPEG, Manitoba, May 14, 2020 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2020 financial results after market close on Thursday, May 21, 2020.

Kane Biotech management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

First Quarter 2020 Results Conference Call Details:
Date:	Thursday, May 21, 2020
Time:	4:30 p.m. ET
Live Call:	1-877-268-9044 (Canada and the United States) 1-706-679-2995 (International)
Replay:	1-404-537-3406
Conference ID:	4697848

The call will also be broadcast live and archived on the Company's website at www.kanebiotech.com under "News/Events" in the Investors section.

About Kane Biotech Inc.

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Corporation has a portfolio of biotechnologies, intellectual property (57 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB^TM, DispersinB, Aledex, bluestem^TM, silkstem^TM, coactiv+^TM and Kane are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE".

For more information, please visit www.kanebiotech.com, or contact:

Marc Edwards
Chief Executive Officer
Kane Biotech Inc.
[phone]	[e-mail]
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc.
[phone]	[e-mail]
Stephen Kilmer
Investor Relations
[phone]	[e-mail]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.